These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34585515)

  • 1. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia.
    Pu X; Sale M; Yang F; Zhang Y; Davis JD; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1412-1421. PubMed ID: 34585515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
    Gao Y; Zhang B; Yang J
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
    Khoury E; Croteau L; Lauzière A; Gaudet D
    Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
    [No Abstract]   [Full Text] [Related]  

  • 5. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
    Pirillo A; Catapano AL
    Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized dosing of evinacumab is predicted to yield reductions in drug expenses.
    Ter Heine R; Rongen GA; Roeters van Lennep J; Rutten JHW
    J Clin Lipidol; 2023; 17(3):401-405. PubMed ID: 36967323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
    Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evinacumab: Mechanism of action, clinical, and translational science.
    Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
    Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
    Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Kastelein JJP; Rubba P; Duell PB; Koseki M; Stroes E; Ali S; Banerjee P; Chan KC; Khilla N; McGinniss J; Pordy R; Zhang Y; Gaudet D
    JACC Adv; 2023 Nov; 2(9):100648. PubMed ID: 38938723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia.
    Duell PB; Warden BA
    Ther Apher Dial; 2022 Dec; 26 Suppl 1():12-17. PubMed ID: 36468314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
    Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
    Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evinacumab for treatment of familial hypercholesterolemia.
    Warden BA; Duell PB
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):739-751. PubMed ID: 34253139
    [No Abstract]   [Full Text] [Related]  

  • 15. Evinacumab: First Approval.
    Markham A
    Drugs; 2021 Jun; 81(9):1101-1105. PubMed ID: 34003472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
    Bajaj A; Cuchel M
    J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Mohamed F; Botha TC; Raal FJ
    Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab.
    Shamsudeen I; McCrindle BW; Hegele RA
    JCEM Case Rep; 2023 May; 1(3):luad058. PubMed ID: 37305647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.
    Harada-Shiba M; Ali S; Gipe DA; Gasparino E; Son V; Zhang Y; Pordy R; Catapano AL
    Atherosclerosis; 2020 Dec; 314():33-40. PubMed ID: 33130482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
    White RT; Sankey KH; Nawarskas JJ
    Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.